MPM BioImpact’s Morphic Holding, Inc. Common Stock MORF Stock Holding History

MPM BioImpact’s Portfolio MORF Stock Details MORF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-369,384	Closed	-$12.6M	–	54
2024 Q2	$12.6M	Buy	369,384 +44,051	+14%	+$1.3M	1.96%	17
2024 Q1	$11.5M	Buy	325,333 +1,591	+0.5%	+$53.3K	1.84%	20
2023 Q4	$9.35M	Buy	323,742 +123,742	+62%	+$2.95M	2.19%	19
2023 Q3	$4.58M	Buy	+200,000	New	+$10.5M	1.22%	26

Other funds holding MORF

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Hoey Investments Coatesville, Pennsylvania $693M AUM 34.99% 1-Year Est. Return

MPM BioImpact's MORF Position: Q3 2024 in Review

MPM BioImpact sold out of Morphic Holding, Inc. Common Stock (MORF) in Q3 2024, closing a stake of 369,384 shares — an estimated $12.6M sold.

MPM BioImpact first reported a position in MORF in Q3 2023 and held it in 4 quarters. The position peaked at $12.6M in Q2 2024. 2 funds tracked by Wall St. Rank hold MORF as of Q3 2024.

MPM BioImpact reported no remaining Morphic Holding, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
MPM BioImpact sold 369,384 Morphic Holding, Inc. Common Stock shares in Q3 2024, an estimated $12.6M.
MPM BioImpact first reported a position in Morphic Holding, Inc. Common Stock in Q3 2023 and held it in 4 quarters.
MPM BioImpact's Morphic Holding, Inc. Common Stock position peaked at $12.6M in Q2 2024.
2 funds tracked by Wall St. Rank held Morphic Holding, Inc. Common Stock as of Q3 2024.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.